Haemonetics (NYSE:HAE) Issues FY 2026 Earnings Guidance

Key Points

• Haemonetics has issued FY 2026 earnings guidance with an expected EPS of 4.700-5.00, slightly below the consensus estimate of 4.866.
• The company's stock opened at $75.81 and has a market cap of $3.64 billion, indicating significant growth potential within the medical instruments sector.
• Current analyst sentiment includes a majority rating of "Moderate Buy", with a consensus price target of $97.30, suggesting optimism in future stock performance.

Haemonetics (NYSE:HAE - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 4.700-5.00 for the period, compared to the consensus earnings per share estimate of 4.866. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several research firms have commented on HAE. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. JMP Securities reissued a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research report on Tuesday, May 20th. Baird R W raised Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. Robert W. Baird assumed coverage on Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price for the company. Finally, Barrington Research reduced their target price on Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a research note on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $87.64.

Haemonetics Price Performance

Shares of Haemonetics stock traded down $1.75 on Friday, hitting $53.88. The company's stock had a trading volume of 2,688,474 shares, compared to its average volume of 818,031. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.99 and a current ratio of 1.72. Haemonetics has a 1 year low of $53.25 and a 1 year high of $94.99. The firm has a fifty day moving average price of $72.88 and a 200-day moving average price of $67.39. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of 16.48, a price-to-earnings-growth ratio of 0.90 and a beta of 0.40.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%. The company had revenue of $321.39 million for the quarter, compared to analysts' expectations of $305.12 million. During the same period in the previous year, the firm posted $1.02 EPS. Haemonetics's revenue was down 4.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HAE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Haemonetics by 6.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock worth $9,923,000 after purchasing an additional 9,051 shares during the last quarter. Caxton Associates LLP acquired a new position in Haemonetics in the first quarter valued at approximately $216,000. United Services Automobile Association acquired a new position in Haemonetics in the first quarter valued at approximately $212,000. Strs Ohio acquired a new position in Haemonetics in the first quarter valued at approximately $140,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock valued at $1,877,000 after acquiring an additional 971 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.